Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TheraGenetics fills new exec VP role

This article was originally published in Clinica

Executive Summary

TheraGenetics (London, UK), a personalised medicine diagnostics company, has appointed Robert McBurney as executive vice-president, a newly-created role. Mr McBurney will be responsible for leading the company’s global business development and partnership strategy. He joins from BG Medicine (Massachusetts), where he served as senior vice-president, R&D and chief scientific officer. During his more than 20 years’ experience in the biopharmaceutical industry, Mr McBurney founded start-up biotech firm Differential Proteomics and has served in senior positions at Cambridge NeuroScience and at the Medical Research Council’s neuroendocrinology unit, Newcastle University, National Institutes of Health, and Cambridge University. TheraGenetics is currently commercialising a portfolio of tests to guide and improve treatment of central nervous system disorders.

You may also be interested in...



Asia Regulatory Forum Update

Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.

Saudi Arabia adopts interim device authorisation regulation

Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.

Canada takes action to increase more adverse event reporting

The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.

Topics

UsernamePublicRestriction

Register

MT040987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel